Since 2016
Engineering the future of vapor.
Na3 Labs was founded on a radical premise: that nicotine delivery could be redesigned from first principles — precision-engineered at the molecular level, manufactured under pharmaceutical-grade protocols, and distributed through a vertically integrated global network. What began as three scientists in a Shenzhen clean-room is now a publicly traded company operating across 23 regulated markets.
Our Philosophy
We believe harm reduction is a design problem, not a marketing one. Every Na3 product undergoes 14,000+ hours of thermal cycling, 300+ chemical assays, and real-world panel testing across five continents before it earns a SKU. Our proprietary NanoCoil™ mesh heating element operates at ±0.5°C precision — the tightest tolerance in the industry — eliminating the thermal degradation that produces harmful byproducts in conventional devices.
Milestones
The Founding — Three Scientists, One Clean-Room
Dr. Liang Wei (materials science, MIT), Sarah Chen (biomedical engineering, Imperial), and Marcus Andrade (supply-chain operations, Wharton) resign from their respective positions at CATL, Dyson, and Amazon. They pool $240K in personal savings to lease a 400m² ISO Class 7 clean-room in Shenzhen Nanshan, with a single mission: rebuild the atomizer from scratch.
NanoCoil™ Patent Granted
After 14 months of R&D and 1,200+ prototype iterations, Na3 files its foundational patent (US 10,842,174) for the NanoCoil™ mesh heating element — a titanium-alloy lattice with 12μm filament diameter that delivers ±0.5°C thermal precision. The patent is granted in the US, EU, CN, JP, and KR simultaneously. Y Combinator invests in the seed round.
Series A — $18M Led by Sequoia China
Sequoia China leads an $18M Series A, joined by Horizons Ventures and Shunwei Capital. The funding enables construction of a 12,000m² GMP-certified production facility in Dongguan, featuring fully automated SMT lines, AI-driven quality inspection (defect rate < 0.003%), and a dedicated toxicology lab for HPHC (Harmful and Potentially Harmful Constituents) testing.
FDA PMTA Submission & EU TPD Compliance
Na3 becomes one of the first independent companies to submit a Pre-Market Tobacco Product Application (PMTA) to the US FDA, covering 23 SKUs across 4 nicotine strengths. Simultaneously, all products achieve EU Tobacco Products Directive (TPD) Article 20 compliance, including the 2ml tank limit and CLP-classified e-liquid packaging. The regulatory team grows to 35 specialists.
Series B — $85M, $450M Valuation
Tiger Global leads an $85M Series B at a $450M pre-money valuation. Na3 uses the capital to build out its global distribution arm: regional hubs in Rotterdam (EMEA), Miami (Americas), and Singapore (APAC), each with bonded warehousing, local compliance teams, and same-week fulfillment capability. The company also acquires BrésilVape, the largest vape distributor in Latin America.
DTC Launch & 1 Million Users
Na3 launches its direct-to-consumer e-commerce platform across 14 markets with age-verified checkout, 5-language support, and real-time inventory sync from the Dongguan MES. Within 8 months the platform surpasses 1 million registered users, with a 42% repeat purchase rate — the highest in the industry. The subscription model (pod auto-replenishment) accounts for 28% of DTC revenue.
Carbon-Neutral Operations Certified
Na3 achieves carbon-neutral certification across all three production facilities (Scope 1+2) and distribution hubs (Scope 3 partial), verified by SGS. The Dongguan factory installs 4.2MW rooftop solar, covers 61% of energy demand. All packaging transitions to FSC-certified recycled cardboard with soy-based ink. The closed-loop pod recycling program launches in 6 EU markets, recovering 73% of post-consumer aluminum.
Series C — $200M, IPO Preparation
General Atlantic and Temasek co-lead a $200M Series C at a $1.8B valuation, marking Na3 as a unicorn. Proceeds fund the construction of a second manufacturing campus in Penang (Malaysia) to serve the APAC region and de-risk single-site dependency. The company begins IPO preparation, appointing Goldman Sachs and Morgan Stanley as joint bookrunners.
NYSE Listing — Ticker $NA3
Na3 Labs Inc. lists on the New York Stock Exchange under ticker $NA3, raising $380M in its IPO at a $2.6B fully diluted valuation. The offering is 4.2× oversubscribed. Founder Dr. Liang Wei rings the opening bell. Proceeds are allocated to: 40% R&D (next-gen heated-tobacco platform), 30% global retail expansion (target: 50 flagship stores by 2026), and 30% strategic M&A.
Gen-3 Platform & 25 Global Stores
Na3 unveils its Gen-3 vapor platform featuring AI-powered flavor profiling, real-time health telemetry (heart rate, SpO2 via optical sensor), and OTA firmware updates. The global retail network reaches 25 owned and authorized locations across 5 continents. R&D headcount surpasses 400, with satellite labs in Cambridge (UK), Lausanne (CH), and Tsukuba (JP).